BioElectronics has completed a double blind, randomized, placebo controlled trial on delayed muscle onset soreness using its ActiPatch product.
ActiPatch utilizes pulsed electromagnetic field therapy to reduce pain, inflammation and heal injured tissue.
The results showed that muscle soreness in runners’ thighs were reduced by using ActiPatch, compared to runners who used a placebo device.
BioElectronics clinical research director Ian Rawe said these results suggest that the company’s ActiPatch device has the potential to be used in sports applications, not just for injury recovery but also injury prevention and improved performance.
"The exposure of these results and our technology at the European Federation of National Associations of Orthopaedics and Traumatology conference, presented by a respected researcher, will be extremely beneficial, and in due course will attract more research in this interesting field," Rawe added.